Medical Advocates
Ribavirin
 
HCV Indications

New and Noteworthy
 General Reports
Adverse Events
Drug Alerts
 Dosage
Monitoring
 Monotherapy
 Combination Therapies


 
HCV Drugs Main Page Main New/Newsworthy Home Page      
Last Update:  February 12, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader 6
New and Noteworthy
     
March 2005
 
General Reports
               
     Journal Papers, Abstracts, and Commentaries
 
  How does ribavirin improve interferon-alpha response rates in hepatitis C virus infection?
 Pawlotsky M.    
J Hepatol. 2005 Jun;42(6):951-3.
 Abstract
Dosage Studies
               
     Journal Papers, Abstracts, and Commentaries
 
  Dosage adjustment of ribavirin based on renal function in Japanese patients with
chronic hepatitis C.
 Maeda Y, Kiribayashi Y, Moriya T, et al 
Ther Drug Monit. 2004 Feb;26(1):9-15
Abstract
 
Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A
Population Pharmacokinetic Analysis.
Bruchfeld A, Lindahl K, Schvarcz R, Stahle L.
Ther Drug Monit 2002Dec;24(6):701-708
Abstract
Monitoring
               

     Journal Papers, Abstracts, and Commentaries
  Ribavirin quantification in combination treatment of chronic hepatitis C.
 Larrat S, Stanke-Labesque F, Plages A, et al
 Antimicrob Agents Chemother 2003 Jan;47(1):124-9
 Abstract
Adverse Events
               
     Journal Papers, Abstracts, and Commentaries
 
  Factors contributing to ribavirin-induced anemia.
 Nomura H, Tanimoto H, Kajiwara E, et al 
J Gastroenterol Hepatol. 2004 Nov;19(11):1312-7
 Abstract
Drug Alerts
               
    Internet Document
 
  FDA DRUG ALERT
 Pulmonary: sarcoidosis or the exacerbation of sarcoidosis has been reported with
REBETOL (ribavirin) Capsules & Intron A (interferon alfa 2b) and should not be used
in patients with creatinine clearance
March 27, 2003
 News Release		  
Monotherapy
               
     Journal Papers, Abstracts, and Commentaries
 
  Efficacy of ribavirin monotherapy following combination therapy with interferon alfa-2b
and ribavirin for patients with chronic hepatitis C.
 Nagayama R, Tanaka A, Ankoh H,et al 
Hepatol Res. 2005 May 2;
Abstract
Combination Therapies
               
     Journal Abstracts, Posters, and Commentaries
 
 
Effects of ribavirin combined with interferon-alpha2b on viral kinetics during first 12 weeks
of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
 Enomoto M, Nishiguchi S, Kohmoto M, et al 
J Viral Hepat. 2004 Sep;11(5):448-54.
 Abstract

FULL-TEXT PDF ARTICLE
Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of
Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients
in the Benelux [ISRCTN53821378].
 Veldt BJ, Brouwer JT, Adler M, et al 
BMC Gastroenterol.2003 Aug 29
 Paper
 
  A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with
chronic hepatitis C.
 Ide T, Okamura T, Kumashiro R, et al.|
 Int J Mol Med 2003 Jun;11(6):729-32
 Abstract
 
Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction
dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized
pilot study.
 eegink CJ, Sentjens RE, Beld MG,  et al
 Viral Hepat 2003 May;10(3):174-82
 Abstract

HCV Drugs Main Page Main New/Newsworthy Home Page      

Ribavirin Hepatitis C Indications
Main Page